Observational studyJournal of neuro-oncology2020
Disparities in glioblastoma survival by case volume: a nationwide observational study.
Observational study in Journal of neuro-oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Social vulnerability and survival among patients with high-grade glioma treated at a tertiary cancer center.Journal of neuro-oncology · 2026Article
- The impact of distance in treating glioblastoma: a retrospective single-center study.Journal of neuro-oncology · 2026Article
- Consequences of Hypoxic Events, Necrosis, and Microvascular Density, in Astrocytoma IDH-Mutant, CNS WHO Grade 4.Medical sciences (Basel, Switzerland) · 2025Article
- Survival prediction in glioblastoma: 10-year follow-up from the Dutch Neurosurgery Quality Registry.Journal of neuro-oncology · 2025Article
- Comparative Clinical-Imaging and Histogenetic Analysis Between Astrocytoma IDH-Mutant Grade 4 and Glioblastoma IDH-Wildtype-Is There Really a Worse One?Diagnostics (Basel, Switzerland) · 2025Article
- Association of hospital volume with survival but not with postoperative mortality in glioblastoma patients in Belgium.Journal of neuro-oncology · 2024Article
- Temporal muscle thickness is not a prognostic predictor in patients with high-grade glioma, an experience at two centers in China.Open medicine (Warsaw, Poland) · 2024Article
- Does waiting for surgery matter? How time from diagnostic MRI to resection affects outcomes in newly diagnosed glioblastoma.Journal of neurosurgery · 2024Article
- The surgical management of diffuse gliomas: Current state of neurosurgical management and future directions.Neuro-oncology · 2023Article
- Glioblastoma management in a lower middle-income country: Nationwide study of compliance with standard care protocols and survival outcomes in Ukraine.Neuro-oncology practice · 2023Article
- The Current State of Adult Glial Tumor Patients' Care in Kazakhstan: Challenges in Diagnosis and Patterns in Survival Outcomes.Biomedicines · 2023Article
- Outcome and characteristics of patients with adult grade 4 diffuse gliomas changing sites of treatment.Journal of cancer research and clinical oncology · 2023Article
- Glioma: bridging the tumor microenvironment, patient immune profiles and novel personalized immunotherapy.Frontiers in immunology · 2023Review
- Aggressiveness of Grade 4 Gliomas of Adults.Clinics and practice · 2022Article
- Diazepam diminishes temozolomide efficacy in the treatment of U87 glioblastoma cell line.CNS neuroscience & therapeutics · 2022Article
- Eighteen years' experience with tumor treating fields in the treatment of newly diagnosed glioblastoma.Frontiers in oncology · 2022Article
- CircRNA circPTK2 Might Suppress Cancer Cell Invasion and Migration of Glioblastoma by Inhibiting miR-23a Maturation.Neuropsychiatric disease and treatment · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHigh hospital case volumes are associated with improved treatment outcomes for numerous diseases. We assessed the association between academic non-profit hospital case volume and survival of adult glioblastoma patients.
methodsFrom the nationwide Finnish Cancer Registry, we identified all adult (≥ 18 years) patients with histopathological diagnoses of glioblastoma from 2000 to 2013. Five university hospitals (treating all glioblastoma patients in Finland) were classified as high-volume (one hospital), middle-volume (one hospital), and low-volume (three hospitals) based on their annual numbers of cases. We estimated one-year survival rates, estimated median overall survival times, and compared relative excess risk (RER) of death between high, middle, and low-volume hospitals.
resultsA total of 2,045 patients were included. The mean numbers of annually treated patients were 54, 40, and 17 in the high, middle, and low-volume hospitals, respectively. One-year survival rates and median survival times were higher and longer in the high-volume (39%, 9.3 months) and medium-volume (38%, 8.9 months) hospitals than in the low-volume (32%, 7.8 months) hospitals. RER of death was higher in the low-volume hospitals than in the high-volume hospital (RER = 1.19, 95% CI 1.07-1.32, p = 0.002). There was no difference in RER of death between the high-volume and medium-volume hospitals (p = 0.690).
conclusionHigher glioblastoma case volumes were associated with improved survival. Future studies should assess whether this association is due to differences in patient-specific factors or treatment quality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.